ipilimumab,nivolumab
bms
['nivo', 'nivolumab', 'gi ', 'ipilimumab', 'pancreatic']
at #asco22, phase 1b/ii study shows benefit of ipilimumab over nivolumab combined with parp inhibitor for apdac. attend updates in oncology 2022 for a gi cancer recap. #pancreaticcancer #cme #cne learn more at 
Leslye M. Heisler Associate Professor of Lung Cancer Excellence @PennMedicine | Faculty @PC31 | Associate Director @PennPrecisMed | Tweets my own